/RLMD
RLMD Stock - Relmada Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$4.35+4.82%
+$0.20 (+4.82%) • Dec 19
88
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+30.3%upside
Target: $5.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RLMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.31 – $4.39
TARGET (TP)$5.67
STOP LOSS$4.00
RISK/REWARD1:3.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.74
52W High$5.12
52W Low$0.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-83,891,036 | $-103,702,000 | $-161,249,000 | $-125,703,492 | $-60,838,673 |
| Net Income | $-79,979,354 | $-98,792,000 | $-157,043,000 | $-125,751,809 | $-59,456,394 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.65 | $-3.28 | $-5.30 | $-7.16 | $-3.81 |
Company Overview
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
29%
Hold / Neutral
4
57%
Sell / Underperform
1
14%
Analyst Consensus🔴 Bearish
2 Bullish5 Neutral/Bearish
Price Targets
$7
Average Target
↑ 67.5% Upside
Now
$1
Low
$7
Average
$13
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 19th 2025 | Mizuho | Upgrade | Outperform | $10 |
| December 5th 2024 | Mizuho | Downgrade | Neutral | $1← $23 |
| September 17th 2024 | Jefferies | Upgrade | Buy | $13← $3.5 |
| June 5th 2024 | Goldman | Downgrade | Sell | $2← $3 |
| October 14th 2022 | Goldman | Downgrade | Neutral | $8← $81 |
| October 14th 2022 | Truist | Downgrade | Hold | $10← $90 |
| October 14th 2022 | Guggenheim | Downgrade | Neutral | - |
| October 13th 2022 | Oppenheimer | Downgrade | Perform | $7← $64 |
Earnings History & Surprises
RLMDBeat Rate
53%
Last 19 quarters
Avg Surprise
-39.0%
EPS vs Estimate
Beats / Misses
10/9
Last 12 quarters
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q1 24
+4.5%
$-0.84vs$-0.88
Q2 24
+20.0%
$-0.72vs$-0.90
Q3 24
+28.9%
$-0.59vs$-0.83
Q4 24
-10.8%
$-0.72vs$-0.65
Q1 25
+11.4%
$-0.62vs$-0.70
Q2 25
-87.1%
$-0.58vs$-0.31
Q3 25
-20.0%
$-0.30vs$-0.25
Q4 25
-650.0%
$-0.30vs$-0.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.03 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.04 | $-0.30 | -650.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.25 | $-0.30 | -20.0% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.31 | $-0.58 | -87.1% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.70 | $-0.62 | +11.4% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.65 | $-0.72 | -10.8% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.83 | $-0.59 | +28.9% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.90 | $-0.72 | +20.0% | ✓ BEAT |
Q1 2024 | Mar 19, 2024 | $-0.88 | $-0.84 | +4.5% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.95 | $-0.73 | +23.2% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.92 | $-0.84 | +8.7% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.88 | $-0.87 | +1.1% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-1.33 | $-1.26 | +5.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-1.40 | $-1.31 | +6.4% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-1.30 | $-1.33 | -2.3% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-1.21 | $-1.40 | -15.7% | ✗ MISS |
Q1 2022 | Mar 23, 2022 | $-1.60 | $-1.80 | -12.5% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-1.62 | $-2.44 | -50.6% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-1.47 | $-1.56 | -6.1% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-1.39 | $-1.34 | +3.6% | ✓ BEAT |
Latest News
Relmada Therapeutics Form4 Filing Shows CEO Sergio Traversa Bought 1,225,500 Shares At An Average Price Of $0.09/Share
📈 PositiveBenzinga•Dec 16, 2025, 02:33 PM
Relmada Therapeutics To Present 6-Month Follow-Up Data From Ongoing Phase 2 Study Of NDV-01 In Development For Non-Muscle Invasive Bladder Cancer, At SUO 2025
➖ NeutralBenzinga•Dec 3, 2025, 12:36 PM
Mizuho Upgrades Relmada Therapeutics to Outperform, Raises Price Target to $10
📈 PositiveBenzinga•Nov 19, 2025, 02:36 PM•Also:
Relmada Therapeutics GAAP EPS of -$0.30
📉 NegativeSeeking Alpha•Nov 13, 2025, 09:10 PM
Relmada Therapeutics Q3 EPS $(0.30) Misses $(0.04) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:03 PM
Relmada Prices $100M Equity Offering Including 40.14M Common Shares At $2.20 Each And 5.32M Pre-Funded Warrants At $2.199 Each
➖ NeutralBenzinga•Nov 4, 2025, 12:16 PM
Relmada Receives FDA Support For Two Registrational Study Paths For NDV-01 In Bladder Cancer, Reports 92% Overall Response At 9 Months With Strong Safety Profile
📈 PositiveBenzinga•Nov 4, 2025, 12:08 PM
Relmada Regains Compliance With Nasdaq $1 Minimum Bid Price Requirement
📈 PositiveBenzinga•Sep 16, 2025, 01:05 PM
Relmada CEO Sergio Traversa Reports 91% Complete Response Rate In Phase 2 NDV 01 Study For Non Muscle Invasive Bladder Cancer
📈 PositiveBenzinga•Sep 10, 2025, 11:18 AM
Relmada Therapeutics CMO Raj S. Pruthi Purchases 55,000 Shares In Open Market On August 29, 2025
📈 PositiveBenzinga•Sep 2, 2025, 03:40 PM
Frequently Asked Questions about RLMD
What is RLMD's current stock price?
Relmada Therapeutics, Inc. (RLMD) is currently trading at $4.35 per share. The stock has moved +4.82% today.
What is the analyst price target for RLMD?
The average analyst price target for RLMD is $5.67, based on 1 analyst.
What sector is Relmada Therapeutics, Inc. in?
Relmada Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RLMD's market cap?
Relmada Therapeutics, Inc. has a market capitalization of $0.32 billion, making it a small-cap company.
Does RLMD pay dividends?
No, Relmada Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
ACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
CBUS
Cibus, Inc.
$1.71
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
Explore stocks similar to RLMD for comparison